Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib

Authors:

Abstract
No abstract available
Funding Information
  • Genentech (OSI4266s)
  • Celegene (AX-CL-BRST-PI-003828)
  • National Cancer Institute (P30CA015704, P30CA047904)

This publication has 43 references indexed in Scilit: